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Introduction 49
After a new biomarker is convincingly associated with disease, the next question is whether it 50 might have clinical/public-health use as a predictive test. Proof of clinical/public-health utility 51 requires absolute (not relative) risks for test results, a valuable risk-reducing intervention, and a 52 comprehensive cost-effectiveness analysis that balances benefits, harms, and costs. Upon 53 biomarker discovery, information required for a comprehensive analysis is usually unavailable. 54
But it remains important to assess preliminarily, without considering costs, benefits, or harms, 55 whether the new biomarker is predictive enough to justify formal cost-effectiveness analyses. 56
Standard metrics reported for binary biomarkers 1 provide at best indirect information 57 about predictiveness for clinical/public-health use. The odds-ratio is a well-known poor measure 58 of predictiveness 2 . When comparing two tests, it is uncommon for one test to have both higher 59 sensitivity and specificity, or both higher positive predictive value (PPV) and lower complement 60 of the negative predictive value (cNPV). Two summary statistics, Youden's Index 3 
and the Area 61
Under the Receiver Operating Characteristic Curve (AUC) statistic (AUC is also used for 62 continuous tests) 4, 5 , have been correctly criticized for not taking predictive values (i.e. absolute 63 risks) into account, and for not permitting differential weighting of false-positive versus false-64 negative errors 6 . The AUC is the probability that someone with disease has higher risk than 65 someone without disease, which requires only the risk ranks, not the absolute risks themselves 4 . 66
Because the AUC for a binary test is the average of 1 and Youden's Index 7 , key criticisms of the 67 two tests are shared. 68
There is a need to better understand the implications of standard diagnostic accuracy 69 metrics for clinical/public-health utility. We reinterpret standard metrics in light of a novel 70 framework for quantifying risk-stratification. Risk-stratification quantifies the ability of a test to 71 separate those at high risk of disease from those at low risk, allowing clinicians to intervene only 72 for those that testing indicates are more likely to develop disease, and not intervene for those that 73 testing indicates will likely not develop disease. We introduce two new broadly applicable, 74 linked statistics that have proven useful in our epidemiologic work on identifying potentially 75 useful biomarker tests for cervical cancer screening. We define mean risk-stratification (MRS) as 76 the average change in risk of disease that a test reveals for tested individuals. We also define a 77 complementary statistic, the Number Needed to Test (NNTest), which quantifies how many 78 people require testing to identify one more disease case than random selection would. We use 79
MRS and NNTest to demonstrate that disease prevalence and test-positivity are crucial for 80 evaluating risk-stratification and interpreting standard metrics. In particular, becaue the 81 maximum MRS is proportional to disease prevalence, little risk-stratification is possible for rare 82 diseases, demonstrating a "high-bar" to justify population-based screening. The novel statistics 83 help place the risk-difference, Youden's index and AUC into perspective: they measure 84 multiplicative relative gains in risk-stratification, which might not imply large absolute gains if 85 disease is rare. Thus AUC cannot be used to rank tests between populations with different 86 disease prevalence, and we show examples from our experience. Our webtool calculates 87 MRS/NNTest (http://analysistools-dev.nci.nih.gov/biomarkerTools). 88 89
Background for Examples: Cervical cancer screening tests 90
Human papillomavirus (HPV) causes almost all cervical cancer 8 , leading to development of 91 prophylactic vaccines and HPV DNA testing for screening. HPV DNA-based screening is 92 starting to replace cervical cytology ("Pap smears"), but many new tests are available or being 93 rapidly developed [9] [10] . For low/middle-income countries, visual inspection with acetic acid 94 (VIA), a simple low-cost, but unreliable and inaccurate test has been proposed 11, 12 . To expedite 95 cervical screening guidelines development 13 , we propose using MRS/NNTest to better interpret 96 standard diagnostic accuracy statistics to identify potentially useful biomarkers for further 97 definitive cost-effectiveness evaluations. 98
To illustrate the use of MRS/NNTest, we present data from 2 collaborations. Colleagues 99 in China evaluated 3 cervical screening tests (HPV testing, cervical cytology, and VIA) in a 100 previously unscreened population of 30,371 women, to select a test as the basis for a future 101 nationwide screening program. 14 Second, to support the development of US cervical screening 102 guidelines, we previously analyzed data on 1.4 million women screened since 2003 in the USA 103 at Kaiser Permanente Northern California (KPNC) with cervical cytology, HPV testing, or both 104 concurrently ("cotesting") 15 . 105 Table 1 shows the standard metrics for each test in China and KPNC (USA). When 106 comparing two tests in the same population, there is usually a dilemma, namely, a tradeoff of 107 sensitivity vs. specificity, or PPV vs. cNPV, which makes it hard to draw firm conclusions on the 108 basis of a single statistic. 109 110
Methods: Mean Risk-stratification and Number Needed to Test 111
In the absence of test results or other pre-test information, each individual can only be assigned 112 as a best guess the same population-average risk. After taking a test, people learn how their 113 predicted individual risks differ from population-average. Tests are most useful when they 114 reveal that risk is far enough from population-average risk to justify a change in management. where P(D+,M+) is a joint probability. The latter form shows that MRS assesses departure from 127 independence akin to Pearson's correlation, the Mantel-Haenszel test 16 , and Lewontin's D' 17 . 128 The eAppendix relates MRS to many statistics, including discretized versions of statistics used 129 for continuous biomarkers 18-22 . 130 An inverse expression of MRS is also useful. A test is only useful if it is substantially 131 better than random selection. Random selection will identify cases by sheer luck: P(D+,M+) 132 would equal P(D+)P(M+). The Number Needed to Test (NNTest), to identify 1 more disease 133 case than random selection is 134
. 135 Therefore, The factor of 2 in MRS merits explanation. 1/MRS is the number needed to test to 152 identify, on average, 1 different outcome than random selection: 0.5 more disease cases and thus 153 also 0.5 fewer non-disease cases. Thus 2/MRS is the number needed to test to identify 1 more 154 disease case and thus also 1 fewer non-disease case, which is a more natural scaling. 155
For a perfect test (PPV=1 and cNPV=0), the equation for MRS (1) reveals that the 156 maximum MRS is 50%, which occurs when disease prevalence and test positivity are both 50%. 157
The maximum MRS is not 100% because even if the PPV yields an increase of nearly 1, then the 158 cNPV can yield only a small decrease, and the two are averaged. MRS can be negative 159 The odds ratio is the cross-product ratio / , hence it is dimensionless. In contrast, MRS is 170 on the scale of risk-differences, and NNTest represents a number of people. In particular, if 171 a,b,c,d represent cell counts (rather than probabilities) with n being their sum then 172
Note that n 2 does not cancel out as it does in the odds ratio. If n is the sample size and a,b,c,d are 174 probabilities (not counts), the asymptotic variance of MRS can be calculated with the delta-175 method 16 on a quadrinomial likelihood for 2x2 tables: 176 . Risk-stratification depends on not only the spread between 186 absolute risks (the risk-difference), but also test-positivity. 187
A rarely positive test, no matter how big the risk-difference, provides little risk-188 stratification. For example, consider the hypothetical use of cervical cytology (contrary to usual 189 practice to make a point), dichotomized simply as cancer or not cancer ("not cancer'' includes all 190 precancerous and negative cytology results). At KPNC, the 5-year PPV for finding a precancer 191 or cancer, following a cytology result of cancer, is 84%, the cNPV is 0.519%, and the overall 192 precancer/cancer prevalence is 0.524% 23 . The risk-difference t=84%-0.519%=83.5% is 193 enormous, suggesting high risk-stratification. However, the probability of having a cytology 194 result of cancer is only 0.006%. Consequently, only with probability 0.006% does a woman get 195 the dramatic risk increase PPV-P(D+)=84%-0.524%=83.5%. Almost all the time (99.994%), 196 she has a trivial risk decrease P(D+)-cNPV=0.524%-0.519%=0.005%. The MRS is 0.01%: only 197 1 extra precancer/cancer on average will be found over 5 years per 10,000 women using this test 198 versus random selection. The NNTest=20,086 is an enormous number of women to screen to 199 improve upon random selection. Thus good risk-stratification requires both a sufficiently large 200 risk-difference and a test that is positive sufficiently often. 201 Youden's index do not imply good risk-stratification if the disease is too rare. Thus: 218
• Disease prevalence defines the maximal amount of risk-stratification that a test can provide. 219
Setting J=1 as a perfect biomarker, the maximum MRS for a disease is 2P(D+)P(D-); minimum 220
NNTest is 1/(P(D+)P(D-)). The rarer the disease, the less risk-stratification is possible. If the 221 maximum risk-stratification is small, every test must inevitably have low risk-stratification This 222 is a reality of general-population cancer screening: on average, screening tests for uncommon 223 diseases such as cancer do not reveal much risk information to tested individuals, and thus, 224 hundreds require screening to identify one more case than would be found by random selection. 225
In Table 1 prevalences. The importance of disease prevalence is illustrated by noting that, the maximum 234 MRS/NNTest (achieved for AUC=1) is also obtained if AUC=0.55 when disease is 10 times as 235 prevalent (dashed line); AUC=0.6 is required if disease is 5 times as prevalent. Thus a perfect 236 marker for a rare disease provides the same risk-stratification as a weakly associated marker for a 237 disease that is 5 or 10 times as prevalent. 238
• The risk-stratification implications of Youden's index or AUC depend on disease prevalence. 240
A test with high Youden's index or AUC in a population with low disease prevalence may 241 provide less risk-stratification than a test with lower Youden's index or AUC in a population 242 with higher disease prevalence. 243
In Table 1 , cotesting at KPNC in the USA has a greater AUC than VIA in China (83% in 244 KPNC vs. 72% in China), but VIA in China has a better MRS (0.7% vs. 1.4%) and NNTest (275 245 vs. 140) than cotesting at KPNC. Cotesting is incontestably more accurate than VIA 12 , but VIA 246 stratifies risk better in an easier setting (unscreened population) than cotesting stratifies risk in a 247 harder setting (heavily screened population). Thus, conducting even VIA in China could 248 identify more treatable precancer (and hence prevent more cervical-cancer death) than cotesting 249 at KPNC. Figure 2 shows that for fixed AUC, the MRS/NNTest are dramatically better as 250 disease becomes more prevalent. 251
• Youden's index is the percent of maximum risk-stratification actually achieved by the test. 253
This helps us interpret the meaning of increases in AUC in terms of risk-stratification. This expression also helps interpret the sometimes obscure meaning of increases in AUC 24, 25 . 261
Since J = 2 × AUC − 1 , each 1% increase in AUC implies a 2% increase in MRS (or decrease in 262 NNTest). Thus MRS doubles from AUC=0.6 to 0.7. An AUC=0.6 is widely considered to be 263 "modest", and indeed, only 20% of the maximum MRS is achieved. An AUC=0.7 is widely 264 considered "good", but only 40% of the maximum MRS is achieved. An AUC=0.9 is required to 265 achieve 80% of the maximum MRS. The top axis of Figure 2 shows how the percent of 266 maximum MRS increases linearly with AUC. As disease becomes rarer, such as for prevalence 267 of 1/10,000, there is little discernible increase in MRS as AUC increases. 268
Similarly, this expression interprets the risk-stratification implied by an odds-ratio. The 269 minimum odds-ratio required to achieve a Youden's index has sensitivity equal to specificity. 270 Table 2 shows the minimum odds-ratio required to achieve each fraction of the maximum MRS 271 (the maximum odds-ratio is always infinity, when sensitivity or specificity are 100%). For 272 example, a marker with odds-ratio of 3.4 can attain no higher than 30% of the maximum MRS. 273
If specificity must be high (say 95%), then OR=3.4 can attain no higher than 10% of the 274 maximum MRS. Seemingly large odds-ratios do not suffice to imply large risk-stratification. 275
The odds-ratios in Table 1 follow this pattern. At KPNC, the 3 tests with the lowest and similar  276 MRS of about 0.3% have odds-ratios varying widely . Similarly, the 4 best tests in China 277 have similar MRS (2.6%-2.8%), but odds-ratios vary widely (108-206). Thus odds-ratios reveal 278 little about risk-stratification. 279
280
• It is important to distinguish rankings of different tests refering to the same population or 281 between populations. Either can be useful depending on the objective. 282 MRS/NNTest and J/AUC will rank the risk-estimation of tests in the same order in the same 283 population because disease prevalence is fixed (see Table 1 ) -in Figure 1 , the MRS increases 284 monotonically with AUC. Thus comparing the MRS/NNTest for 2 tests in the same population 285 is equivalent to comparing their J/AUCs, which is useful for hypothesis testing. However, when 286 prevalence varies across populations, J/AUC do not necessarily even rank test risk-stratification 287 correctly according to MRS/NNTest. For example, a test with AUC=1 has less risk-stratification 288 than a test with AUC>0.55 for a disease 10 times as prevalent (Figure 2, dashed line) . 289
Consequently, comparing the risk-stratification of the same test among populations with different 290 prevalence requires MRS/NNTest to account for differing disease prevalence across populations. 291
292
• MRS and NNTest could be calculated by combining an estimate of Youden's index (or AUC) 293 in one study with disease prevalence from a target population. 294 MRS/NNTest can be calculated by combining an estimate of Youden's index from case-control 295 data with disease prevalence from a target population, to quickly assess the risk-stratification 296 implications of a new biomarker in the target population. However, Youden's index for a new 297 test might not be transportable between populations. For example, Youden's index and AUC for 298 a given test or test combination are larger in China than at KPNC ( Table 1) . Although specificity is 308 acknowledged as the most important quality of biomarkers for rare diseases 26 , specificity can be 309 artificially boosted by increasing test-negativity. MRS/NNTest balances specificity and test-310 negativity. Also Spec − P(M −) represents the increase in specificity versus random selection 311 (for random selection, specificity equals test-negativity). In Table 1 , the test at KPNC with the 312 best MRS/NNTest is cotesting, which has the lowest specificity but also has the highest 313 sensitivity and the lowest test-negativity at 92.5%. The minimal required test specificity is set by 314 test-negativity. For example, 95% of US women are HPV-negative. Thus HPV tests must have 315 specificity >95% in the US, and 96% specificity is required to achieve an NNTest of 100 in the 316 US. As a rule of thumb, attaining an NNTest of 100 requires that specificity exceed test-317 negativity by 1%. 318 319 Discussion 320
After a biomarker-disease association is confirmed, assessment of the predictive capacity of the 321 biomarker is necessary to preliminarily understand the clinical/public-health implications of the 322 biomarker. We introduced two linked metrics, MRS and NNTest, for quantifying risk-323 stratification from binary diagnostic tests. MRS is the average change in risk that a test reveals 324 for an individual patient. NNTest is the number needed to test to identify 1 more disease case 325 than random selection. We presented 3 major findings on using MRS/NNTest to better 326 understand the clinical/public-health implications of standard diagnostic accuracy statistics. 327
First, MRS/NNTest demonstrate that there is little risk-stratification possible for rare 328 diseases or for rarely positive tests. Thus screening for rare diseases requires a strong 329 justification. China has 3 times the precancer/cancer prevalence of KPNC in the USA, and all 330 tests, including VIA, the weakest cervical screening test, provide far more risk-stratification in 331
China than at KPNC. 332
Second, MRS/NNTest demonstrate that the risk-difference, Youden's index, and AUC 333 measure multiplicative relative gains in risk-stratification, which might not imply large absolute 334 gains if disease is too rare or if the test is too rarely positive. An AUC=0.6 achieves only 20% of 335 maximum risk-stratification. An AUC=0.9 is required to achieve 80%. These findings are 336 generally in accord with intuition that AUC appropriately casts 'pessimism' on the power of risk 337 prediction 24 . Within a population, Youden's index and AUC will rank tests for risk-338 stratification in the same order as MRS/NNTest, although rankings may differ across populations 339 with differing disease prevalence. 340
Third, for uncommon diseases, MRS/NNTest provide a sufficient criterion that ensures 341 high risk-stratification: a high difference between specificity and test-negativity. Thus 342 MRS/NNTest emphasizes the dominant role of specificity, but penalizes for artificially 343 increasing specificity at the expense of test-negativity. Although researchers tend to focus on 344 sensitivity when designing tests, focusing on the difference between specificity and test-345 negativity would optimize risk-stratification. 346
This first paper presents the concept of MRS/NNTest. We will extend MRS/NNTest to 347 continuous outcomes to quantify risk-stratification from risk-prediction models and to compare 348 MRS/NNTest to new statistics for evaluating risk models, such as decision curves 27 . Research on 349 estimating MRS/NNTest from different study designs and statistical models is important. For 350 uncommon diseases like cancer, the MRS is small and NNTest is large, and more experience is 351 necessary to develop an intuitive sense of sufficient MRS/NNTest in various settings. 352
Although etiologic epidemiology progresses using association statistics, standard diagnostic 353 accuracy statistics used in applied epidemiology and public-health are easy to misinterpret. There 354 is a torrent of new biomarkers and risk-prediction models, but evaluating them remains 355 challenging, and many are used clinically without sufficient formal study 28 Infinity Infinity Table 2 . The minimum odds-ratios required for a marker to account for each fraction of the maximum possible risk-stratification. The right column provides the minimum odds-ratio if specificity must be high (set at 95%). pre val en ce= 1/1 ,00 0 prevalence=1/100 0% 20% 40% 60% 80% 100% % of maximum risk stratification achieved, which also equals Youden's Index
